Cessation of Long Term NAs vs. Keeping on NAs Among CHB Patients (CNAVK)

Recruiting now · Phase 4

Conditions studied: Chronic Hepatitis B

In brief

To Identify the collected cases who can stop NAs safely with satisfactory clinical outcome including sustain viral remission and HBsAg clearance among chronic hepatitis B(CHB) patients.

Key facts

Study ID

NCT03792919

Run by

Humanity & Health Medical Group Limited

People needed

2000

Starts

2018-12-01

Expected to finish

2025-12-31

Last updated by the study team

2025-03-24

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• HBsAg positive, HBeAg negative, antibody to HBeAg-positive;
• Stable administration of anti-HBV neucleos(t)ides analogue mono therapy for at least more than one and a half year;
• Demonstration of undetectable HBV DNA on three occasions, each at least 6 months apart, which is consistent with the APASL stopping rule;
• Patients read, understand the consent form, and signed the study consent.

You may not qualify if…

• Patient with other liver diseases;
• Patient with concurrent hepatitis viruses or HIV infection;
• Patients are reluctant to stop their anti-HBV treatment.

Where it is running

• Humanity & Health Research Centre — Hong Kong, Hong Kong SAR, Hong Kong (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.